Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-10	€0.0610	+12.96%	91
26-07-09	€0.0540	-10.74%	0
26-07-08	€0.0605	+12.04%	5,340
26-07-07	€0.0540	-1.82%	350
26-07-06	€0.0550	+1.85%	350

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG Other stock markets 2026-07-07			5-day change	1st Jan Change
0.0540 ^EUR	-1.82%		0.00%	+309.09%

Market Cap	144K 165K 133K 123K 233K 15.71M 237K 1.59M 624K 7.74M 619K 605K 26.61M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.28M 9.1M 8.41M 15.95M 1.08B 16.22M 109M 42.7M 530M 42.36M 41.43M 1.82B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

1 day	-1.82%
Current month	-11.48%
1 month	+0.93%
3 months	+33.33%
6 months	+315.38%
Current year	+309.09%

1 week	0.05	0.06
1 month	0.05	0.06
Current year	0.01	0.23
1 year	0	0.23
3 years	0	6.4
5 years	0	20.15
10 years	0	36.78

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	2023-08-31
Sebastian Werner DFI	Director of Finance/CFO	-	2022-05-31

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news : Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Course Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Hans Tanner BRD	Director/Board Member	75	2017-05-31
Karin Louise Dorrepaal BRD	Director/Board Member	65	2012-09-30
Markus Guilherme Dieken BRD	Director/Board Member	-	2019-05-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-12-26	Gregor Siebert	Buy	Director	1,121	0.0016%
21-01-11	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
20-06-07	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	-1.82%	0.00%	+542.86%	-99.11%	497K
LONZA GROUP AG	+0.58%	+2.06%	+2.92%	+10.86%	50.73B
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+385.40%	+586.81%	39.73B
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+25.57%	-5.28%	34.69B
BEONE MEDICINES AG	-1.36%	+0.35%	+17.88%	+55.14%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+35.46%	26.76B
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	16.8B
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+63.97%	+122.60%	15.37B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.76%	+21.11%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+10.29%	-31.35%	12.85B
Average	-0.58%	-0.75%	+118.41%	+77.36%	24.39B
Weighted average by Cap.	-0.48%	-0.23%	+80.69%	+124.32%

	2021	2022
Net sales	7.13M 8.15M 6.58M 6.07M 11.52M 777M 11.72M 78.56M 30.85M 383M 30.6M 29.93M 1.32B	33.25M 38.01M 30.67M 28.32M 53.74M 3.63B 54.65M 366M 144M 1.79B 143M 140M 6.14B
Net income	-21.79M -24.91M -20.09M -18.56M -35.22M -2.38B -35.81M -240M -94.29M -1.17B -93.52M -91.48M -4.02B	-579K -662K -534K -493K -936K -63.13M -952K -6.38M -2.51M -31.1M -2.49M -2.43M -107M
Net Debt	13.77M 15.74M 12.7M 11.73M 22.26M 1.5B 22.63M 152M 59.59M 740M 59.1M 57.82M 2.54B	9.72M 11.12M 8.97M 8.28M 15.72M 1.06B 15.98M 107M 42.08M 522M 41.74M 40.83M 1.8B